Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $105
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the price target from $95 to $105.
Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the price target from $95 to $105.